Research ArticleAccepted Article
Gastrointestinal adverse drug reaction profile of etanercept: real world data from patients and healthcare professionals
Jette A. van Lint, Naomi T. Jessurun, Sander W. Tas, Bart J.F. van den Bemt, Michael T. Nurmohamed, Martijn B.A. van Doorn, Phyllis I. Spuls, Astrid M. van Tubergen, Peter M. ten Klooster, Eugene P. van Puijenbroek, Frank Hoentjen and Harald E. Vonkeman
The Journal of Rheumatology May 2021, jrheum.201373; DOI: https://doi.org/10.3899/jrheum.201373
Jette A. van Lint
Netherlands Pharmacovigilance Centre Lareb, ’s-Hertogenbosch, NL; Department of Rheumatology & Clinical Immunology, Amsterdam UMC, location Academic Medical Center, University of Amsterdam, Amsterdam Infection & Immunity Institute and Amsterdam Rheumatology & immunology Center (ARC), Amsterdam, NL; Department of Pharmacy, Sint Maartenskliniek, Nijmegen NL; Department of Pharmacy, Radboud University Medical Center, Nijmegen, NL; Amsterdam Rheumatology & immunology Center (ARC) | Reade, Amsterdam, NL; Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, VU University Medical Center, Amsterdam, NL; Department of Dermatology, Erasmus MC, University Medical Center, Rotterdam, NL; Department of Dermatology, Public Health and Epidemiology; Immunity and Infections, Amsterdam UMC, Location Academic Medical Center, Amsterdam, NL; Department of Rheumatology, Maastricht University Medical Center, Maastricht, NL; Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, NL; Transparency in Healthcare B.V., Hengelo, NL; Department of Psychology, Health & Technology, University of Twente, Enschede, NL; Department of Pharmacotherapy, Epidemiology & Economics, University of Groningen, Groningen, NL; Department of Gastroenterology, Radboud University Medical Center, Nijmegen, NL; Department of Rheumatology and Clinical Immunology, Medisch Spectrum Twente, Enschede, NL. The Dutch Biologic Monitor was supported by the Netherlands Organisation for Health Research and Development (ZonMw), grant number 848050005. No funding was received for the conduct of this specific study. Corresponding author: Jette A. van Lint,Netherlands Pharmacovigilance Centre Lareb, Goudsbloemvallei 7, 5237 MH, ’s-Hertogenbosch. E-mail: j.vanlint@lareb.nl
Naomi T. Jessurun
Netherlands Pharmacovigilance Centre Lareb, ’s-Hertogenbosch, NL; Department of Rheumatology & Clinical Immunology, Amsterdam UMC, location Academic Medical Center, University of Amsterdam, Amsterdam Infection & Immunity Institute and Amsterdam Rheumatology & immunology Center (ARC), Amsterdam, NL; Department of Pharmacy, Sint Maartenskliniek, Nijmegen NL; Department of Pharmacy, Radboud University Medical Center, Nijmegen, NL; Amsterdam Rheumatology & immunology Center (ARC) | Reade, Amsterdam, NL; Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, VU University Medical Center, Amsterdam, NL; Department of Dermatology, Erasmus MC, University Medical Center, Rotterdam, NL; Department of Dermatology, Public Health and Epidemiology; Immunity and Infections, Amsterdam UMC, Location Academic Medical Center, Amsterdam, NL; Department of Rheumatology, Maastricht University Medical Center, Maastricht, NL; Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, NL; Transparency in Healthcare B.V., Hengelo, NL; Department of Psychology, Health & Technology, University of Twente, Enschede, NL; Department of Pharmacotherapy, Epidemiology & Economics, University of Groningen, Groningen, NL; Department of Gastroenterology, Radboud University Medical Center, Nijmegen, NL; Department of Rheumatology and Clinical Immunology, Medisch Spectrum Twente, Enschede, NL. The Dutch Biologic Monitor was supported by the Netherlands Organisation for Health Research and Development (ZonMw), grant number 848050005. No funding was received for the conduct of this specific study. Corresponding author: Jette A. van Lint,Netherlands Pharmacovigilance Centre Lareb, Goudsbloemvallei 7, 5237 MH, ’s-Hertogenbosch. E-mail: j.vanlint@lareb.nl
Sander W. Tas
Netherlands Pharmacovigilance Centre Lareb, ’s-Hertogenbosch, NL; Department of Rheumatology & Clinical Immunology, Amsterdam UMC, location Academic Medical Center, University of Amsterdam, Amsterdam Infection & Immunity Institute and Amsterdam Rheumatology & immunology Center (ARC), Amsterdam, NL; Department of Pharmacy, Sint Maartenskliniek, Nijmegen NL; Department of Pharmacy, Radboud University Medical Center, Nijmegen, NL; Amsterdam Rheumatology & immunology Center (ARC) | Reade, Amsterdam, NL; Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, VU University Medical Center, Amsterdam, NL; Department of Dermatology, Erasmus MC, University Medical Center, Rotterdam, NL; Department of Dermatology, Public Health and Epidemiology; Immunity and Infections, Amsterdam UMC, Location Academic Medical Center, Amsterdam, NL; Department of Rheumatology, Maastricht University Medical Center, Maastricht, NL; Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, NL; Transparency in Healthcare B.V., Hengelo, NL; Department of Psychology, Health & Technology, University of Twente, Enschede, NL; Department of Pharmacotherapy, Epidemiology & Economics, University of Groningen, Groningen, NL; Department of Gastroenterology, Radboud University Medical Center, Nijmegen, NL; Department of Rheumatology and Clinical Immunology, Medisch Spectrum Twente, Enschede, NL. The Dutch Biologic Monitor was supported by the Netherlands Organisation for Health Research and Development (ZonMw), grant number 848050005. No funding was received for the conduct of this specific study. Corresponding author: Jette A. van Lint,Netherlands Pharmacovigilance Centre Lareb, Goudsbloemvallei 7, 5237 MH, ’s-Hertogenbosch. E-mail: j.vanlint@lareb.nl
Bart J.F. van den Bemt
Netherlands Pharmacovigilance Centre Lareb, ’s-Hertogenbosch, NL; Department of Rheumatology & Clinical Immunology, Amsterdam UMC, location Academic Medical Center, University of Amsterdam, Amsterdam Infection & Immunity Institute and Amsterdam Rheumatology & immunology Center (ARC), Amsterdam, NL; Department of Pharmacy, Sint Maartenskliniek, Nijmegen NL; Department of Pharmacy, Radboud University Medical Center, Nijmegen, NL; Amsterdam Rheumatology & immunology Center (ARC) | Reade, Amsterdam, NL; Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, VU University Medical Center, Amsterdam, NL; Department of Dermatology, Erasmus MC, University Medical Center, Rotterdam, NL; Department of Dermatology, Public Health and Epidemiology; Immunity and Infections, Amsterdam UMC, Location Academic Medical Center, Amsterdam, NL; Department of Rheumatology, Maastricht University Medical Center, Maastricht, NL; Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, NL; Transparency in Healthcare B.V., Hengelo, NL; Department of Psychology, Health & Technology, University of Twente, Enschede, NL; Department of Pharmacotherapy, Epidemiology & Economics, University of Groningen, Groningen, NL; Department of Gastroenterology, Radboud University Medical Center, Nijmegen, NL; Department of Rheumatology and Clinical Immunology, Medisch Spectrum Twente, Enschede, NL. The Dutch Biologic Monitor was supported by the Netherlands Organisation for Health Research and Development (ZonMw), grant number 848050005. No funding was received for the conduct of this specific study. Corresponding author: Jette A. van Lint,Netherlands Pharmacovigilance Centre Lareb, Goudsbloemvallei 7, 5237 MH, ’s-Hertogenbosch. E-mail: j.vanlint@lareb.nl
Michael T. Nurmohamed
Netherlands Pharmacovigilance Centre Lareb, ’s-Hertogenbosch, NL; Department of Rheumatology & Clinical Immunology, Amsterdam UMC, location Academic Medical Center, University of Amsterdam, Amsterdam Infection & Immunity Institute and Amsterdam Rheumatology & immunology Center (ARC), Amsterdam, NL; Department of Pharmacy, Sint Maartenskliniek, Nijmegen NL; Department of Pharmacy, Radboud University Medical Center, Nijmegen, NL; Amsterdam Rheumatology & immunology Center (ARC) | Reade, Amsterdam, NL; Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, VU University Medical Center, Amsterdam, NL; Department of Dermatology, Erasmus MC, University Medical Center, Rotterdam, NL; Department of Dermatology, Public Health and Epidemiology; Immunity and Infections, Amsterdam UMC, Location Academic Medical Center, Amsterdam, NL; Department of Rheumatology, Maastricht University Medical Center, Maastricht, NL; Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, NL; Transparency in Healthcare B.V., Hengelo, NL; Department of Psychology, Health & Technology, University of Twente, Enschede, NL; Department of Pharmacotherapy, Epidemiology & Economics, University of Groningen, Groningen, NL; Department of Gastroenterology, Radboud University Medical Center, Nijmegen, NL; Department of Rheumatology and Clinical Immunology, Medisch Spectrum Twente, Enschede, NL. The Dutch Biologic Monitor was supported by the Netherlands Organisation for Health Research and Development (ZonMw), grant number 848050005. No funding was received for the conduct of this specific study. Corresponding author: Jette A. van Lint,Netherlands Pharmacovigilance Centre Lareb, Goudsbloemvallei 7, 5237 MH, ’s-Hertogenbosch. E-mail: j.vanlint@lareb.nl
Martijn B.A. van Doorn
Netherlands Pharmacovigilance Centre Lareb, ’s-Hertogenbosch, NL; Department of Rheumatology & Clinical Immunology, Amsterdam UMC, location Academic Medical Center, University of Amsterdam, Amsterdam Infection & Immunity Institute and Amsterdam Rheumatology & immunology Center (ARC), Amsterdam, NL; Department of Pharmacy, Sint Maartenskliniek, Nijmegen NL; Department of Pharmacy, Radboud University Medical Center, Nijmegen, NL; Amsterdam Rheumatology & immunology Center (ARC) | Reade, Amsterdam, NL; Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, VU University Medical Center, Amsterdam, NL; Department of Dermatology, Erasmus MC, University Medical Center, Rotterdam, NL; Department of Dermatology, Public Health and Epidemiology; Immunity and Infections, Amsterdam UMC, Location Academic Medical Center, Amsterdam, NL; Department of Rheumatology, Maastricht University Medical Center, Maastricht, NL; Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, NL; Transparency in Healthcare B.V., Hengelo, NL; Department of Psychology, Health & Technology, University of Twente, Enschede, NL; Department of Pharmacotherapy, Epidemiology & Economics, University of Groningen, Groningen, NL; Department of Gastroenterology, Radboud University Medical Center, Nijmegen, NL; Department of Rheumatology and Clinical Immunology, Medisch Spectrum Twente, Enschede, NL. The Dutch Biologic Monitor was supported by the Netherlands Organisation for Health Research and Development (ZonMw), grant number 848050005. No funding was received for the conduct of this specific study. Corresponding author: Jette A. van Lint,Netherlands Pharmacovigilance Centre Lareb, Goudsbloemvallei 7, 5237 MH, ’s-Hertogenbosch. E-mail: j.vanlint@lareb.nl
Phyllis I. Spuls
Netherlands Pharmacovigilance Centre Lareb, ’s-Hertogenbosch, NL; Department of Rheumatology & Clinical Immunology, Amsterdam UMC, location Academic Medical Center, University of Amsterdam, Amsterdam Infection & Immunity Institute and Amsterdam Rheumatology & immunology Center (ARC), Amsterdam, NL; Department of Pharmacy, Sint Maartenskliniek, Nijmegen NL; Department of Pharmacy, Radboud University Medical Center, Nijmegen, NL; Amsterdam Rheumatology & immunology Center (ARC) | Reade, Amsterdam, NL; Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, VU University Medical Center, Amsterdam, NL; Department of Dermatology, Erasmus MC, University Medical Center, Rotterdam, NL; Department of Dermatology, Public Health and Epidemiology; Immunity and Infections, Amsterdam UMC, Location Academic Medical Center, Amsterdam, NL; Department of Rheumatology, Maastricht University Medical Center, Maastricht, NL; Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, NL; Transparency in Healthcare B.V., Hengelo, NL; Department of Psychology, Health & Technology, University of Twente, Enschede, NL; Department of Pharmacotherapy, Epidemiology & Economics, University of Groningen, Groningen, NL; Department of Gastroenterology, Radboud University Medical Center, Nijmegen, NL; Department of Rheumatology and Clinical Immunology, Medisch Spectrum Twente, Enschede, NL. The Dutch Biologic Monitor was supported by the Netherlands Organisation for Health Research and Development (ZonMw), grant number 848050005. No funding was received for the conduct of this specific study. Corresponding author: Jette A. van Lint,Netherlands Pharmacovigilance Centre Lareb, Goudsbloemvallei 7, 5237 MH, ’s-Hertogenbosch. E-mail: j.vanlint@lareb.nl
Astrid M. van Tubergen
Netherlands Pharmacovigilance Centre Lareb, ’s-Hertogenbosch, NL; Department of Rheumatology & Clinical Immunology, Amsterdam UMC, location Academic Medical Center, University of Amsterdam, Amsterdam Infection & Immunity Institute and Amsterdam Rheumatology & immunology Center (ARC), Amsterdam, NL; Department of Pharmacy, Sint Maartenskliniek, Nijmegen NL; Department of Pharmacy, Radboud University Medical Center, Nijmegen, NL; Amsterdam Rheumatology & immunology Center (ARC) | Reade, Amsterdam, NL; Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, VU University Medical Center, Amsterdam, NL; Department of Dermatology, Erasmus MC, University Medical Center, Rotterdam, NL; Department of Dermatology, Public Health and Epidemiology; Immunity and Infections, Amsterdam UMC, Location Academic Medical Center, Amsterdam, NL; Department of Rheumatology, Maastricht University Medical Center, Maastricht, NL; Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, NL; Transparency in Healthcare B.V., Hengelo, NL; Department of Psychology, Health & Technology, University of Twente, Enschede, NL; Department of Pharmacotherapy, Epidemiology & Economics, University of Groningen, Groningen, NL; Department of Gastroenterology, Radboud University Medical Center, Nijmegen, NL; Department of Rheumatology and Clinical Immunology, Medisch Spectrum Twente, Enschede, NL. The Dutch Biologic Monitor was supported by the Netherlands Organisation for Health Research and Development (ZonMw), grant number 848050005. No funding was received for the conduct of this specific study. Corresponding author: Jette A. van Lint,Netherlands Pharmacovigilance Centre Lareb, Goudsbloemvallei 7, 5237 MH, ’s-Hertogenbosch. E-mail: j.vanlint@lareb.nl
Peter M. ten Klooster
Netherlands Pharmacovigilance Centre Lareb, ’s-Hertogenbosch, NL; Department of Rheumatology & Clinical Immunology, Amsterdam UMC, location Academic Medical Center, University of Amsterdam, Amsterdam Infection & Immunity Institute and Amsterdam Rheumatology & immunology Center (ARC), Amsterdam, NL; Department of Pharmacy, Sint Maartenskliniek, Nijmegen NL; Department of Pharmacy, Radboud University Medical Center, Nijmegen, NL; Amsterdam Rheumatology & immunology Center (ARC) | Reade, Amsterdam, NL; Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, VU University Medical Center, Amsterdam, NL; Department of Dermatology, Erasmus MC, University Medical Center, Rotterdam, NL; Department of Dermatology, Public Health and Epidemiology; Immunity and Infections, Amsterdam UMC, Location Academic Medical Center, Amsterdam, NL; Department of Rheumatology, Maastricht University Medical Center, Maastricht, NL; Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, NL; Transparency in Healthcare B.V., Hengelo, NL; Department of Psychology, Health & Technology, University of Twente, Enschede, NL; Department of Pharmacotherapy, Epidemiology & Economics, University of Groningen, Groningen, NL; Department of Gastroenterology, Radboud University Medical Center, Nijmegen, NL; Department of Rheumatology and Clinical Immunology, Medisch Spectrum Twente, Enschede, NL. The Dutch Biologic Monitor was supported by the Netherlands Organisation for Health Research and Development (ZonMw), grant number 848050005. No funding was received for the conduct of this specific study. Corresponding author: Jette A. van Lint,Netherlands Pharmacovigilance Centre Lareb, Goudsbloemvallei 7, 5237 MH, ’s-Hertogenbosch. E-mail: j.vanlint@lareb.nl
Eugene P. van Puijenbroek
Netherlands Pharmacovigilance Centre Lareb, ’s-Hertogenbosch, NL; Department of Rheumatology & Clinical Immunology, Amsterdam UMC, location Academic Medical Center, University of Amsterdam, Amsterdam Infection & Immunity Institute and Amsterdam Rheumatology & immunology Center (ARC), Amsterdam, NL; Department of Pharmacy, Sint Maartenskliniek, Nijmegen NL; Department of Pharmacy, Radboud University Medical Center, Nijmegen, NL; Amsterdam Rheumatology & immunology Center (ARC) | Reade, Amsterdam, NL; Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, VU University Medical Center, Amsterdam, NL; Department of Dermatology, Erasmus MC, University Medical Center, Rotterdam, NL; Department of Dermatology, Public Health and Epidemiology; Immunity and Infections, Amsterdam UMC, Location Academic Medical Center, Amsterdam, NL; Department of Rheumatology, Maastricht University Medical Center, Maastricht, NL; Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, NL; Transparency in Healthcare B.V., Hengelo, NL; Department of Psychology, Health & Technology, University of Twente, Enschede, NL; Department of Pharmacotherapy, Epidemiology & Economics, University of Groningen, Groningen, NL; Department of Gastroenterology, Radboud University Medical Center, Nijmegen, NL; Department of Rheumatology and Clinical Immunology, Medisch Spectrum Twente, Enschede, NL. The Dutch Biologic Monitor was supported by the Netherlands Organisation for Health Research and Development (ZonMw), grant number 848050005. No funding was received for the conduct of this specific study. Corresponding author: Jette A. van Lint,Netherlands Pharmacovigilance Centre Lareb, Goudsbloemvallei 7, 5237 MH, ’s-Hertogenbosch. E-mail: j.vanlint@lareb.nl
Frank Hoentjen
Netherlands Pharmacovigilance Centre Lareb, ’s-Hertogenbosch, NL; Department of Rheumatology & Clinical Immunology, Amsterdam UMC, location Academic Medical Center, University of Amsterdam, Amsterdam Infection & Immunity Institute and Amsterdam Rheumatology & immunology Center (ARC), Amsterdam, NL; Department of Pharmacy, Sint Maartenskliniek, Nijmegen NL; Department of Pharmacy, Radboud University Medical Center, Nijmegen, NL; Amsterdam Rheumatology & immunology Center (ARC) | Reade, Amsterdam, NL; Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, VU University Medical Center, Amsterdam, NL; Department of Dermatology, Erasmus MC, University Medical Center, Rotterdam, NL; Department of Dermatology, Public Health and Epidemiology; Immunity and Infections, Amsterdam UMC, Location Academic Medical Center, Amsterdam, NL; Department of Rheumatology, Maastricht University Medical Center, Maastricht, NL; Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, NL; Transparency in Healthcare B.V., Hengelo, NL; Department of Psychology, Health & Technology, University of Twente, Enschede, NL; Department of Pharmacotherapy, Epidemiology & Economics, University of Groningen, Groningen, NL; Department of Gastroenterology, Radboud University Medical Center, Nijmegen, NL; Department of Rheumatology and Clinical Immunology, Medisch Spectrum Twente, Enschede, NL. The Dutch Biologic Monitor was supported by the Netherlands Organisation for Health Research and Development (ZonMw), grant number 848050005. No funding was received for the conduct of this specific study. Corresponding author: Jette A. van Lint,Netherlands Pharmacovigilance Centre Lareb, Goudsbloemvallei 7, 5237 MH, ’s-Hertogenbosch. E-mail: j.vanlint@lareb.nl
Harald E. Vonkeman
Netherlands Pharmacovigilance Centre Lareb, ’s-Hertogenbosch, NL; Department of Rheumatology & Clinical Immunology, Amsterdam UMC, location Academic Medical Center, University of Amsterdam, Amsterdam Infection & Immunity Institute and Amsterdam Rheumatology & immunology Center (ARC), Amsterdam, NL; Department of Pharmacy, Sint Maartenskliniek, Nijmegen NL; Department of Pharmacy, Radboud University Medical Center, Nijmegen, NL; Amsterdam Rheumatology & immunology Center (ARC) | Reade, Amsterdam, NL; Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, VU University Medical Center, Amsterdam, NL; Department of Dermatology, Erasmus MC, University Medical Center, Rotterdam, NL; Department of Dermatology, Public Health and Epidemiology; Immunity and Infections, Amsterdam UMC, Location Academic Medical Center, Amsterdam, NL; Department of Rheumatology, Maastricht University Medical Center, Maastricht, NL; Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, NL; Transparency in Healthcare B.V., Hengelo, NL; Department of Psychology, Health & Technology, University of Twente, Enschede, NL; Department of Pharmacotherapy, Epidemiology & Economics, University of Groningen, Groningen, NL; Department of Gastroenterology, Radboud University Medical Center, Nijmegen, NL; Department of Rheumatology and Clinical Immunology, Medisch Spectrum Twente, Enschede, NL. The Dutch Biologic Monitor was supported by the Netherlands Organisation for Health Research and Development (ZonMw), grant number 848050005. No funding was received for the conduct of this specific study. Corresponding author: Jette A. van Lint,Netherlands Pharmacovigilance Centre Lareb, Goudsbloemvallei 7, 5237 MH, ’s-Hertogenbosch. E-mail: j.vanlint@lareb.nl
Published eLetters
eLetters are comments published online only and are not peer-reviewed. Publication of eLetter submissions is not guaranteed, and all submissions are reviewed and edited at the discretion of The Journal's staff.
If you wish to publish Letters to the Editor or Correspondence, please submit through our online submission system ScholarOne Manuscripts.
Jump to comment:
No eLetters have been published for this article.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 3
1 Mar 2024
Accepted manuscript
Gastrointestinal adverse drug reaction profile of etanercept: real world data from patients and healthcare professionals
Jette A. van Lint, Naomi T. Jessurun, Sander W. Tas, Bart J.F. van den Bemt, Michael T. Nurmohamed, Martijn B.A. van Doorn, Phyllis I. Spuls, Astrid M. van Tubergen, Peter M. ten Klooster, Eugene P. van Puijenbroek, Frank Hoentjen, Harald E. Vonkeman
The Journal of Rheumatology May 2021, jrheum.201373; DOI: 10.3899/jrheum.201373
Accepted manuscript
Gastrointestinal adverse drug reaction profile of etanercept: real world data from patients and healthcare professionals
Jette A. van Lint, Naomi T. Jessurun, Sander W. Tas, Bart J.F. van den Bemt, Michael T. Nurmohamed, Martijn B.A. van Doorn, Phyllis I. Spuls, Astrid M. van Tubergen, Peter M. ten Klooster, Eugene P. van Puijenbroek, Frank Hoentjen, Harald E. Vonkeman
The Journal of Rheumatology May 2021, jrheum.201373; DOI: 10.3899/jrheum.201373